000			04078nam a2200409 i 4500
999			_c112759 _d112759
001			112759
003			ES-MaUEC
005			20230209141520.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			181212s2019 gw a o |||| 0|eng d
020			_a9783030012076
024	7		_a10.1007/978-3-030-01207-6 _2doi
040			_bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC254.5 _b2019 EB
245	0	0	_aRegulatory and Economic Aspects in Oncology _cedited by Evelyn Walter
264		1	_aCham _bSpringer International Publishing _c2019
300			_a1 recurso en línea (VII, 205 páginas) _b14 ilustraciones, 12 ilustraciones a color
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF
490	0		_aRecent Results in Cancer Research _x0080-0015 _v213
490	0		_aMedicine (Springer-11650)
505	0		_aThe growing health burden of cancer: a global epidemiological overview.-Cost of Cancer Care: Health expenditures and economic impact -- Innovation in R&D: An answer to cancer -- The Evaluation of Benefits, Harms and Costs of Cancer Screening -- Oncology from a HTA and health economic perspective -- Heterogeneous recommendations for oncology products among different HTA systems: a comparative assessment -- Outcomes in oncology: clinical vs. patient-reported outcome performance measures -- The value of patient-reported outcome in health economic decision making: a changing landscape in oncology -- Approaches to capture value in oncology -- Orphan durgs in oncology -- Recent developments in health economic modeling of cancer therapies -- Drug pricing and value in oncology -- Pharmaceutical price regulation of cancer treatments -- Regulatory and evidence requirements and the changing landscape in regulation for marketing authorization -- Looking for Willingness to Pay (WTP) Threshold for a QALY in oncology -- Equity and patient access to innovative cancer treatments. .
520	3		_aThis book explores a wide range of topics of importance to all those who have an interest in economic methods for assessment of the efficacy and effectiveness of new cancer treatments and in regulatory measures relating to the marketing authorization and pricing of such treatments. It also examines drug pricing and drug price regulation in different countries and explores the changing landscape in marketing authorization and its regulation. These issues are becoming increasingly important with the introduction of expensive targeted cancer therapies, which are placing a substantial strain on healthcare healthcare budgets. Payer authorities have to determine whether the use of targeted therapies yields clinical benefits that justify their cost. In the simplest terms, cost-effectiveness analysis quantifies the ratio between the extent to which an intervention raises healthcare costs and the extent to which it improves health outcomes. Rigorous cost-effectiveness analyses translate all health outcomes into quality-adjusted life years. On the other hand, in order to sustain innovation, price regulation must be coupled with efforts to ensure that drug companies are still able to recoup their investments in high-risk and high-cost research programs. Ultimately, decisions regarding health care expenditure are also a reflection of society's willingness to pay.
988			_aSpringer_Medicine_2019
650		7	_aCáncer _2embne _9139308 _xAspectos económicos
650		7	_aCáncer _2embne _9139308 _xPolítica gubernamental
700	1		_aWalter, Evelyn. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
710	2		_aSpringerLink (Online service) _9106996
776	0	8	_iPrinted edition: _z9783030012069
776	0	8	_iPrinted edition: _z9783030012083
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-01207-6 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_dz _feng _ggw _h0 _b02/2023 _eb _zSI